MoneyWorks4Me

The total revenue for the quarter ended June 2026 remained nearly unchanged at Rs. 18136.80 millions.A humble growth in net profit of 17.13% reported in the quarter ended June 2026 to Rs. 4285.20  millions from Rs. 3658.60 millions.Operating profit for the quarter ended June 2026 rose to 5978.70 millions as compared to 5184.30 millions of corresponding quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 18136.80 17383.50 4.33 18136.80 17383.50 4.33 69290.50 64091.50 8.11
Other Income 753.70 728.40 3.47 753.70 728.40 3.47 2881.40 2755.80 4.56
PBIDT 5978.70 5184.30 15.32 5978.70 5184.30 15.32 21802.20 19701.80 10.66
Interest 59.10 58.20 1.55 59.10 58.20 1.55 249.90 114.30 118.64
PBDT 5919.60 5126.10 15.48 5919.60 5126.10 15.48 21552.30 19587.50 10.03
Depreciation 197.50 194.80 1.39 197.50 194.80 1.39 759.60 718.00 5.79
PBT 5722.10 4931.30 16.04 5722.10 4931.30 16.04 20792.70 18869.50 10.19
TAX 1436.90 1272.70 12.90 1436.90 1272.70 12.90 5272.50 4725.10 11.58
Deferred Tax -31.80 -5.00 536.00 -31.80 -5.00 536.00 -107.20 27.20 -494.12
PAT 4285.20 3658.60 17.13 4285.20 3658.60 17.13 15520.20 14144.40 9.73
Equity 212.50 212.50 0.00 212.50 212.50 0.00 212.50 212.50 0.00
PBIDTM(%) 32.96 29.82 10.53 32.96 29.82 10.53 31.46 30.74 2.36
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..